Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

Ted W. Johnson, Helen Y. Zou, Paul Richardson et al.|Molecular Cancer Therapeutics|2013

Cited by 4